TP53, which encodes the tumour-suppressor protein p53, is the most frequently mutated
gene across all cancer types. The presence of mutant p53 predisposes to cancer …

A drug must engage its intended target to achieve its therapeutic effect. However,
conclusively measuring target engagement (TE) in situ is challenging. This complicates …

The tumor suppressor p53 is often inactivated via its interaction with endogenous inhibitors
mouse double minute 4 homolog (MDM4 or MDMX) or mouse double minute 2 homolog …

MATTERS ARISING NATURE METHODS sites annotated by Huang et al. 2 (P= 0.17; Fig.
1c). Even though we identified significant differences in the melting behavior of …

Kinome-wide profiling platforms have comprehensively identified the relevant kinases that
are targeted by numerous protein kinase inhibitors. However, recent projects have begun to …

Peptide stapling is a method for designing macrocyclic alpha‐helical inhibitors of protein–
protein interactions. However, obtaining a cell‐active inhibitor can require significant …

The KEAP1/Nrf2 pathway senses and responds to changes in intracellular oxidative stress.
Mutations that result in constitutive activation of Nrf2 are present in several human tumors …

The mouse double minute 4 (MDM4) is emerging from the shadow of its more famous
relative MDM2 and is starting to steal the limelight, largely due to its therapeutic possibilities …

Impairment of the p53 pathway is a critical event in cancer. Therefore, reestablishing p53
activity has become one of the most appealing anticancer therapeutic strategies. Here, we …

Stapled peptides have emerged as a new class of targeting molecules with high binding
affinity and specificity for intracellular undruggable targets. Their ability to penetrate cell …